BioSpace News Archive

Sales of SEK 514 (382) million, corresponding to an increase of 35 percent in SEK. Consumables increased by 9 percent, Genomics 33 percent, Technology decreased by 12 percent. The organic growth was 4 percent.

Indivior PLC announced its financial results for the period ending December 31, 2021.

Invitae, a leading medical genetics company, announced the availability of FusionPlex Dx® and LiquidPlex Dx™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic products.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the “safe to proceed” letter from the U.S. Food and Drug Administration for the Company’s investigational new drug application for STP707, its lead siRNA drug candidate.

Promore Pharma AB announces that the first subject has been included in the company’s phase II study with the company’s drug candidate ensereptide for the prevention of skin scarring.

Third Harmonic Bio, a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation, launched with the close of a Series B financing that brings the total capital raised to date to $155 million.

Tetra Bio-Pharma Inc. is proud to announce the approval of a $4.5M CDN participative loan from the ministère de l’Économie et de l’Innovation (MEI) under the BioMed Propulsion Program, managed by Investissement Québec (IQ).

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new leadership for its Human Health business.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. Eastern Time.

Milestone Pharmaceuticals Inc. today announced the appointment of David Bharucha , M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022.